Ozempic Gastroparesis Lawsuit: What to Know About Stomach Paralysis Claims

As of October 2026, 4,025 lawsuits were pending in a federal multidistrict litigation (MDL) in the Eastern District of Pennsylvania. MDLs combine several similar lawsuits to make the legal process more efficient.

The GLP-1 products liability litigation, MDL No. 3094, includes claims that Ozempic and other GLP-1 medicines can cause serious gastrointestinal injuries, including gastroparesis, often called stomach paralysis. The drug manufacturers deny the allegations.  

U.S. District Judge Karen S. Marston presides over the litigation. The court continues to manage pretrial proceedings, including issues involving expert evidence, even as new lawsuits are added to the MDL. No Ozempic gastroparesis lawsuit has gone to trial and the federal MDL has not announced a settlement program.

More recently, researchers have found stronger associations between GLP-1 use and gastroparesis, which may strengthen the plaintiffs’ arguments at trial.

“Stomach paralysis” is a plain-language term for a condition in which the stomach empties food unusually slowly or not at all. The clinical name is gastroparesis. Research has recently found a link between gastroparesis and GLP-1 drugs such as Ozempic.

A 2026 study in The Journal of Nuclear Medicine found people taking GLP-1 drugs were about 2.7 times more likely to receive a new gastroparesis diagnosis after a gastric emptying test than people not taking the drugs. However, because the study looked back at existing records, it cannot prove GLP-1 drugs caused gastroparesis.

A 2023 observational study in JAMA found an association between GLP-1 agonist use for weight loss and a higher risk of diagnosed gastroparesis than with bupropion-naltrexone, another weight-loss drug combination. Still, the study cannot establish that the medications caused an individual patient’s condition.

In January 2025, the U.S. Food and Drug Administration also added language to Ozempic’s prescribing information that the drug is not recommended for people who already have severe gastroparesis.

Severe stomach problems after using Ozempic or another GLP-1 drug can be more than just nausea or digestive issues. Gastroparesis symptoms can make it difficult to eat, keep food down, stay hydrated or maintain your weight. If you have had these symptoms while taking Ozempic, Wegovy or a similar medication, you should see a medical professional as soon as possible.

A diagnosis generally requires medical testing, which can document delayed stomach emptying while ruling out a physical blockage.

If you have had ongoing stomach problems like these while taking Ozempic or a similar GLP-1 drug, you may qualify for a lawsuit review. A diagnosis of gastroparesis, emergency treatment, hospital stays, repeated doctor visits or records of severe symptoms can help a legal team decide if your case may be connected to a possible claim.

People who took Ozempic or another semaglutide or GLP-1 medication and were later diagnosed with a serious digestive condition may qualify for a lawsuit. These conditions may include gastroparesis, delayed stomach emptying, ileus or an intestinal blockage. A gastroparesis diagnosis confirmed by a gastric emptying study and medical records documenting severe, persistent symptoms can also matter when evaluating a potential claim.

You may wish to request a case review if you used Ozempic, Wegovy, Rybelsus, Mounjaro, Zepbound or a similar drug and then experienced severe gastrointestinal symptoms.

Consumer Notice can provide a free case review to determine whether you qualify for an Ozempic gastroparesis lawsuit. Fill out the form and an experienced attorney will contact you to discuss your case. There is no cost, and you are not required to pursue a lawsuit.

Be prepared to share the specific medication you used, your diagnosis and how long your severe symptoms lasted.

As of October 2026, there have been no trials or settlements in the federal litigation involving gastrointestinal injuries from Ozempic and other GLP-1 drugs. The cases in MDL 3094 are still at the pretrial stage, which means the court and the parties are addressing common issues before any individual cases are set for trial.

Any future settlement agreement would be based on the evidence in each individual’s case.

A lawsuit review may not ensure that a claim will be accepted, a settlement reached or that compensation is available. Those considering a claim should keep relevant records now, such as prescription information, medical test results, hospital records and documentation of when symptoms first appeared.

Ozempic and semaglutide have also been the subject of separate lawsuits based on claims of sudden vision loss. These cases concern non-arteritic anterior ischemic optic neuropathy, or NAION, a condition of the optic nerve that can lead to sudden and possibly permanent vision loss. However, the manufacturers deny that their GLP-1 drugs cause NAION, and current research has not found a causal link.

These Ozempic blindness lawsuits are distinct from the gastroparesis and other gastrointestinal injury claims. These separate lawsuits have also been combined into a single multidistrict litigation (MDL No. 3163) in the Eastern District of Pennsylvania.